DBV Technologies (FR:DBV)
:DBV
Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€3.62
€0.10(13.73%)
At close: 4:00 PM EST
€3.62
€0.10(13.73%)
Day’s Range― - ―
52-Week Range€1.45 - €4.50
Previous CloseN/A
Volume1.76M
Average Volume (3M)1.12M
Market Cap
€835.91M
Enterprise Value€439.45M
Total Cash (Recent Filing)€229.20M
Total Debt (Recent Filing)€6.10M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Jul 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding296,061,500
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.26Price Target Upside-10.08% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€2.75M
Bulls Say, Bears Say
Bulls Say
Proprietary EPIT Platform (Viaskin)DBV's Viaskin is a differentiated platform technology that targets food-allergy desensitization via epicutaneous delivery. As a platform, EPIT could be extended to multiple allergens and indications, creating durable IP-driven barriers, scalable product lines, and licensing opportunities if clinical success continues.
Low Leverage / Balance Sheet FlexibilityVery low reported leverage gives DBV structural financial flexibility to fund development or negotiate favorable financing terms. This reduces immediate solvency pressure, supports multi-month operational runway, and lowers refinancing risk compared with highly levered peers while clinical programs progress.
Clear Commercialization And Licensing PathwayThe company's explicit model—product sales of Viaskin plus licensing/milestones—creates multiple durable revenue levers post-approval. Commercialization and partner licensing can produce recurring sales, royalties and milestone income, enabling diversified, scalable cash flows if regulatory success is achieved.
Bears Say
Zero TTM Revenue And Large Net LossDBV's lack of trailing revenue and substantial recurring losses are structural constraints: ongoing negative profitability depletes equity, limits reinvestment without external capital, and increases dependence on successful clinical/commercial milestones to generate sustainable cash flow over the medium term.
Sustained Negative Operating And Free Cash FlowHigh and persistent cash burn translates accounting losses into real liquidity depletion, pressuring runway and forcing recurring financing. This structural cash-flow gap constrains program scale-up, increases dilution risk, and raises the execution burden to secure funding before commercialization.
Clinical-stage Dependency And Financing RelianceAs a clinical-stage biotech with no commercial sales, DBV's progress depends on trial outcomes and access to capital. This structural reliance on external financing exposes shareholders to dilution and timing risk, and makes long-term execution contingent on regulatory success and favorable funding markets.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.45 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €835.91M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Jul 29, 2026 which is in 46 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Apr 30, 2026. The company reported -€0.019 earnings per share for the quarter, beating the consensus estimate of -€0.023 by €0.004.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 296,061,500 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.019 in its last earnings report, beating expectations of -€0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
DBV Stock 12 Month Forecast
Average Price Target
€3.26
▼(-10.08% Downside)
Technical Analysis
Options Prices
Currently, No data available
---